Karydas Daphne
SEC Form 4 insider trading activity
Karydas Daphne has filed 5 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Sep 17, 2026.
On the most recent filing, Karydas Daphne is listed as Director at Mineralys Therapeutics, Inc. Inside the rolling window, Karydas Daphne reported no open-market purchases and 4 open-market sales totaling $926K in MLYS. The largest disclosed transaction in the window is a sale of 15,000 MLYS shares on Nov 13, 2025, worth $690K.
Companies traded
Other insiders at MLYS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$926K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Karydas Daphne made?
Karydas Daphne has filed 5 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does Karydas Daphne trade?
Karydas Daphne has filed SEC Form 4 disclosures for 1 company, including MLYS.
When was Karydas Daphne's most recent SEC Form 4 filing?
Karydas Daphne's most recent SEC Form 4 filing on Tracefour is dated Sep 17, 2026.
What is Karydas Daphne's total buy and sell value in the current window?
Inside the rolling retention window, Karydas Daphne bought $0 and sold $926K based on SEC Form 4 filings.
What was Karydas Daphne's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 15,000 MLYS shares on 2025-11-13, worth $690K, per SEC Form 4 filings.